Platelets and arterial thrombosis: Evolving role of platelet GPVI as an antithrombotic drug target

Proceedings of the Indian National Science Academy

Volumn 80, Issue 2, 2014, Pages 289-299

  Misra, A ^a   Dikshit, M ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Anti platelet drugs; Collagen; GPVI; Platelets; Thrombosis

Indexed keywords

BLOOD VESSELS; COLLAGEN; DISEASES;

ACUTE CORONARY SYNDROMES; ANTI-PLATELET DRUGS; EXPERIMENTAL APPROACHES; FUNCTIONAL ATTRIBUTE; GPVI; SEQUENCE OF EVENTS; THERAPEUTIC STRATEGY; THROMBOSIS;

PLATELETS;

EID: 84905990307     PISSN: 03700046     EISSN: None     Source Type: Journal    
DOI: 10.16943/ptinsa/2014/v80i2/55107     Document Type: Article

References (57)

1. Arthur J F, Dunkley S and Andrews R K (2007) Platelet glycoprotein VI-related clinical defects Br J Haematol 139 363-372
2. Arthur J F, Gardiner E E, Matzaris M, Taylor S G, Wijeyewickrema L, Ozaki Y, Kahn M L, Andrews R K and Berndt M C (2005) Glycoprotein VI is associated with GPIb-IX-V on the membrane of resting and activated platelets Thromb Haemost 93 716-723
3. Barnes M J, Knight C G and Farndale R W (1998) The collagenplatelet interaction Curr Opin Hematol 5 314-320
4. Bender M, Hagedorn I and Nieswandt B (2011) Genetic and antibody-induced glycoprotein VI deficiency equally protects mice from mechanically and FeCl(3)-induced thrombosis J Thromb Haemost 9 1423-1426
5. Bertrand M E, Rupprecht H J, Urban P and Gershlick a H (2000) Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS) Circulation 102 624-629
6. Bhatt D L (2008) What makes platelets angry: diabetes, fibrinogen, obesity, and impaired response to antiplatelet therapy? J Am Coll Cardiol 52 1060-1061
7. Bigalke B, Elvers M, Schonberger T and Gawaz M (2011) Platelet and soluble glycoprotein VI - novel applications in diagnosis and therapy Curr Drug Targets 12 1821-1830
8. Boylan B, Chen H, Rathore V, Paddock C, Salacz M, Friedman K D, Curtis B R, Stapleton M, Newman D K, Kahn M L and Newman P J (2004) Anti-GPVI-associated ITP: an acquired platelet disorder caused by autoantibodymediated clearance of the GPVI/FcRgamma-chain complex from the human platelet surface Blood 104 1350-1355
9. Bultmann A, Herdeg C, Li Z, Munch G, Baumgartner C, Langer H, Kremmer E, Geisler T, May A, Ungerer M and Gawaz M (2006) Local delivery of soluble platelet collagen receptor glycoprotein VI inhibits thrombus formation in vivo Thromb Haemost 95 763-766
10. Chew D P, Bhatt D L, Sapp S and Topol E J (2001) Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials Circulation 103 201-206
11. Clemetson K J, Mcgregor J L, James E, Dechavanne M and Luscher E F (1982) Characterization of the platelet membrane glycoprotein abnormalities in Bernard-Soulier syndrome and comparison with normal by surfacelabelling techniques and high-resolution two-dimensional gel electrophoresis J Clin Invest 70 304-311
12. Deckmyn H, Stassen J M, Vreys I, Van Houtte E, Sawyer R T and Vermylen J (1995) Calin from Hirudo medicinalis, an inhibitor of platelet adhesion to collagen, prevents plateletrich thrombosis in hamsters Blood 85 712-719
13. Dikshit D K, Dikshit M, Siddiqui T I, Kumar A, Bhata R S, Jain G K, Barthwal M K, Misra A, Khanna V and Prakash P (2012) Chiral 1-(4- methylphenylmethyl)-5-oxopyrrolidine-2-carboxamides as inhibitors of collagen induced platelet activation and adhesion PCT/IN2012/000032, WO2012104866 A1
14. Dumont B, Minullina I, Loyau S, Monteiro R C, Lacapere J J, Arocas V and Jandrot-Perrus M (2006) Chimeric Fc receptors identify ligand binding regions in human glycoprotein VI J Mol Biol 361 877-887
15. Fareed J, Callas D, Hoppensteadt D A, Lewis B E, Bick R L and Walenga J M (1999) Antithrombin agents as anticoagulants and antithrombotics: implications in drug development Semin Hematol 36 42-56
16. Furlan a J, Eyding D, Albers G W, Al-Rawi Y, Lees K R, Rowley H A, Sachara C, Soehngen M, Warach S and Hacke W (2006) Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset Stroke 37 1227-1231
17. Gardell S J, Duong L T, Diehl R E, York J D, Hare T R, Register R B, Jacobs J W, Dixon R A and Friedman P A (1989) Isolation, characterization, and cDNA cloning of a vampire bat salivary plasminogen activator J Biol Chem264 17947-17952
18. Goldschmidt Pj L N, Crawford Le (2002). Atherosclerosis and Coronary Artery Disease In Platelets (Ed: AD Michelson) 37-383 Academic Press
19. Grothusen C, Umbreen S, Konrad I, Stellos K, Schulz C, Schmidt B, Kremmer E, Teebken O, Massberg S, Luchtefeld M, Schieffer B and Gawaz M (2007) EXP3179 inhibits collagen-dependent platelet activation via glycoprotein receptor-VI independent of AT1-receptor antagonism: potential impact on atherothrombosis Arterioscler Thromb Vasc Biol 27 1184-1190
20. Gruner S, Prostredna M, Aktas B, Moers A, Schulte V, Krieg T, Offermanns S, Eckes B and Nieswandt B (2004) Antiglycoprotein VI treatment severely compromises hemostasis in mice with reduced alpha2beta1 levels or concomitant aspirin therapy Circulation 110 2946-2951
21. Gruner S, Prostredna M, Koch M, Miura Y, Schulte V, Jung S M, Moroi M and Nieswandt B (2005) Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice Blood 105 1492-1499
22. Harsfalvi J, Stassen J M, Hoylaerts M F, Van Houtte E, Sawyer R T, Vermylen J and Deckmyn H (1995) Calin from Hirudo medicinalis, an inhibitor of von Willebrand factor binding to collagen under static and flow conditions Blood 85 705-11
23. Herr a B (2009) Direct evidence of a native GPVI dimer at the platelet surface J Thromb Haemost 7 1344-1346
24. Horii K, Kahn M L and Herr a B (2006) Structural basis for platelet collagen responses by the immune-type receptor glycoprotein VI Blood 108 936-942
25. Jung S M, Tsuji K and Moroi M (2009) Glycoprotein (GP) VI dimer as a major collagen-binding site of native platelets: direct evidence obtained with dimeric GPVI-specific Fabs J Thromb Haemost 7 1347-1355
26. Jung S M and Moroi M (2008) Platelet glycoprotein VI Adv Exp Med Biol 640 53-63
27. Kato-Takagaki K, Mizukoshi Y, Yoshizawa Y, Akazawa D, Torii Y, Ono K, Tanimura R, Shimada I and Takahashi H (2009) Structural and interaction analysis of glycoprotein VIbinding peptide selected from a phage display library J Biol Chem 284 10720-10727
28. Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B and Stoll G (2007) Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding Circulation 115 2323-2330
29. Kunicki T J, Cheli Y, Moroi M and Furihata K (2005) The influence of N-linked glycosylation on the function of platelet glycoprotein VI Blood 106 2744-2749
30. Laslett L J, Alagona P, Jr., Clark B A, Drozda J P, Jr., Saldivar F, Wilson S R, Poe C and Hart M (2012) The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology J Am Coll Cardiol 60 S1-49
31. Li H, Lockyer S, Concepcion A, Gong X, Takizawa H, Guertin M, Matsumoto Y, Kambayashi J, Tandon N N and Liu Y (2007) The Fab fragment of a novel anti-GPVI monoclonal antibody, OM4, reduces in vivo thrombosis without bleeding risk in rats Arterioscler Thromb Vasc Biol 27 1199-1205
32. Liu J, Gao B B, Clermont a C, Blair P, Chilcote T J, Sinha S, Flaumenhaft R and Feener E P (2011) Hyperglycemiainduced cerebral hematoma expansion is mediated by plasma kallikrein Nat Med 17 206-210
33. Maree a O and Fitzgerald D J (2007) Variable platelet response to aspirin and clopidogrel in atherothrombotic disease Circulation 115 2196-2207
34. Massberg S, Konrad I, Bultmann A, Schulz C, Munch G, Peluso M, Lorenz M, Schneider S, Besta F, Muller I, Hu B, Langer H, Kremmer E, Rudelius M, Heinzmann U, Ungerer M and Gawaz M (2004) Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo Faseb J 18 397-399
35. Massberg S, Gawaz M, Gruner S, Schulte V, Konrad I, Zohlnhofer D, Heinzmann U and Nieswandt B (2003) A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo J Exp Med 197 41-49
36. Miura Y, Takahashi T, Jung S M and Moroi M (2002) Analysis of the interaction of platelet collagen receptor glycoprotein VI (GPVI) with collagen. A dimeric form of GPVI, but not the monomeric form, shows affinity to fibrous collagen J Biol Chem 277 46197-46204
37. Morita A, Isawa H, Orito Y, Iwanaga S, Chinzei Y and Yuda M (2006) Identification and characterization of a collageninduced platelet aggregation inhibitor, triplatin, from salivary glands of the assassin bug, Triatoma infestans Febs J 273 2955-2962
38. Moroi M, Jung S M, Okuma M and Shinmyozu K (1989) A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion J Clin Invest 84 1440-1445
39. Nieswandt B and Watson S P (2003) Platelet-collagen interaction: is GPVI the central receptor? Blood 102 449-461
40. Nieswandt B, Bergmeier W, Schulte V, Rackebrandt K, Gessner J E and Zirngibl H (2000) Expression and function of the mouse collagen receptor glycoprotein VI is strictly dependent on its association with the FcRgamma chain J Biol Chem 275 23998-24002
41. O'connor M N, Smethurst P A, Davies L W, Joutsi-Korhonen L, Onley D J, Herr a B, Farndale R W and Ouwehand W H (2006) Selective blockade of glycoprotein VI clustering on collagen helices J Biol Chem 281 33505-33510
42. Ono K, Ueda H, Yoshizawa Y, Akazawa D, Tanimura R, Shimada I and Takahashi H (2010) Structural basis for platelet antiaggregation by angiotensin II type 1 receptor antagonist losartan (DuP-753) via glycoprotein VI J Med Chem 53 2087-2093
43. Sabatine M S, Cannon C P, Gibson C M, Lopez-Sendon J L, Montalescot G, Theroux P, Lewis B S, Murphy S A, Mccabe C H and Braunwald E (2005) Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study Jama 294 1224-1232
44. Santoro S A (1999) Platelet surface collagen receptor polymorphisms: variable receptor expression and thrombotic/hemorrhagic risk Blood 93 3575-3577
45. Santoro S A (1986) Identification of a 160,000 dalton platelet membrane protein that mediates the initial divalent cationdependent adhesion of platelets to collagen Cell 46 913-920
46. Savage B, Almus-Jacobs F and Ruggeri Z M (1998) Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow Cell 94 657-666
47. Savage B, Saldivar E and Ruggeri Z M (1996) Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor Cell 84 289-297
48. Sixma J J, Van Zanten G H, Huizinga E G, Van Der Plas R M, Verkley M, Wu Y P, Gros P and De Groot P G (1997). Platelet adhesion to collagen: an update Thromb Haemost 78 434-438
49. Smith S C, Jr., Collins A, Ferrari R, Holmes D R, Jr., Logstrup S, Mcghie D V, Ralston J, Sacco R L, Stam H, Taubert K, Wood D A and Zoghbi W A (2012) Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke) J Am Coll Cardiol 60 2343-2348
50. Steinhubl S R, Berger P B, Mann J T, Fry E T, Delago A, Wilmer C and Topol E J (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial Jama 288 2411-2420
51. Stoll G, Kleinschnitz C and Nieswandt B (2008) Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment Blood 112 3555-3562
52. Takayama H, Hosaka Y, Nakayama K, Shirakawa K, Naitoh K, Matsusue T, Shinozaki M, Honda M, Yatagai Y, Kawahara T, Hirose J, Yokoyama T, Kurihara M and Furusako S (2008) A novel antiplatelet antibody therapy that induces cAMP-dependent endocytosis of the GPVI/Fc receptor gamma-chain complex J Clin Invest 118 1785-1795
53. Tardy B, Lecompte T, Boelhen F, Tardy-Poncet B, Elalamy I, Morange P, Gruel Y, Wolf M, Francois D, Racadot E, Camarasa P, Blouch M T, Nguyen F, Doubine S, Dutrillaux F, Alhenc-Gelas M, Martin-Toutain I, Bauters A, Ffrench P, De Maistre E, Grunebaum L, Mouton C, Huisse M G, Gouault-Heilmann M and Lucke V (2006) Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin Blood 108 1492-1496
54. Ungerer M, Rosport K, Bultmann A, Piechatzek R, Uhland K, Schlieper P, Gawaz M and Munch G (2011) Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans Circulation 123 1891-1899
55. Witt W, Baldus B, Bringmann P, Cashion L, Donner P and Schleuning W D (1992) Thrombolytic properties of Desmodus rotundus (vampire bat) salivary plasminogen activator in experimental pulmonary embolism in rats Blood 79 1213-1217
56. Yoshida S, Sudo T, Niimi M, Tao L, Sun B, Kambayashi J, Watanabe H, Luo E and Matsuoka H (2008) Inhibition of collagen-induced platelet aggregation by anopheline antiplatelet protein, a saliva protein from a malaria vector mosquito Blood 111 2007-2014
57. Yusuf S, Zhao F, Mehta S R, Chrolavicius S, Tognoni G and Fox K K (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without STsegment elevation N Engl J Med 345 494-502.